Loading…

Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma

Lung adenocarcinoma (LADC) is classified into five main histological subtypes with distinct clinicopathologic characteristics: lepidic-predominant adenocarcinoma (LPA), acinar-predominant adenocarcinoma (APA), papillary-predominant adenocarcinoma (PPA), micropapillary-predominant adenocarcinoma (MPA...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2021-01, Vol.12 (11), p.3222-3229
Main Authors: Li, Yan, Tan, Yan, Hu, Song, Xie, Jun, Yan, Zhantao, Zhang, Xian, Zong, Yun, Han-Zhang, Han, Li, Qing, Li, Chong
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c403t-693bceb23a09362bd350ce9d3a15dfa19966d5db38201a4680044e3afa9ce793
cites
container_end_page 3229
container_issue 11
container_start_page 3222
container_title Journal of Cancer
container_volume 12
creator Li, Yan
Tan, Yan
Hu, Song
Xie, Jun
Yan, Zhantao
Zhang, Xian
Zong, Yun
Han-Zhang, Han
Li, Qing
Li, Chong
description Lung adenocarcinoma (LADC) is classified into five main histological subtypes with distinct clinicopathologic characteristics: lepidic-predominant adenocarcinoma (LPA), acinar-predominant adenocarcinoma (APA), papillary-predominant adenocarcinoma (PPA), micropapillary-predominant adenocarcinoma (MPA) and solid-predominant adenocarcinoma (SPA). However, the mutational profiles of predominant histological subtypes have not been well defined. In this study, we aimed to reveal the genomic landscape of 5 main histological subtypes. We performed next-generation sequencing (NGS) in a cohort of 86 stage I invasive adenocarcinoma (IAC) patients, using a customized panel including 168 cancer-associated genes. Our analysis identified a total of 302 genomic alterations. Five subtypes showed different mutation profiles with LPA, APA, PPA, MPA and SPA had an average mutation rate of 1.95 (range: 0-5), 2.56 (range: 1-6), 3.5 (range: 1-7), 3.75 (range: 1-8) and 6.05 (range: 2-12), respectively (p=4.17e-06). Driver mutations occurred in 96.55% (83/86) of all patients. EGFR (73.3%), KRAS (9.3%), ALK (4.7%) and MET (4.7%) are the most commonly mutated lung cancer driver genes, TP53 is the top mutated tumor suppressor gene. SPA patients harbored more driver mutations and higher frequency of TP53 than LPA patients. Interestingly, mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p=0.001). No patients from other four cohorts harbored mutations. We revealed distinctive mutation landscape of the 5 major histological subtypes of LADC, evident by distinctive average mutation rate with SPA and LPA having the highest and lowest average mutation rate, respectively. SPA patients showed higher mutation rate of LRP1B and higher rates for PD-L1 positivity, indicating that SPA patients may have better response to immunotherapy.
doi_str_mv 10.7150/jca.51405
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8100815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2598309353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-693bceb23a09362bd350ce9d3a15dfa19966d5db38201a4680044e3afa9ce793</originalsourceid><addsrcrecordid>eNpdkd9rFDEQx4MottQ--A9IwBd9uJrs7K-8CKWoPThQ7L2H2WR2zbGbnMnuwf335tpaqvOSgXz4MDNfxt5KcdXISnzaGbyqZCmqF-xcttCsVF2XL5_1Z-wypZ3IBapoSnjNzgBUUzcgz1ncYhxoJsvv6PdC3jg_8GuP4zG5xEPPf0SyYXIe_cxvXZrDGAZncOR3Szcf95S48_wnJTL3khkH4mu-9gdM7kB8s5x8lnwwGLM8TPiGvepxTHT5-F6w7dcv25vb1eb7t_XN9WZlSgHzqlbQGeoKQKGgLjoLlTCkLKCsbI9S5d1sZTtoCyGxrFshypIAe1SGGgUX7PODdr90E1lDfo446n10E8ajDuj0vz_e_dJDOOhWCtHKKgs-PApiyKdJs55cMjSO6CksSRdVUecAJJQZff8fugtLzFc8UaqFvEEFmfr4QJkYUorUPw0jhT5lqXOW-j7LzL57Pv0T-Tc5-AOTTJtV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598309353</pqid></control><display><type>article</type><title>Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central (PMC)</source><creator>Li, Yan ; Tan, Yan ; Hu, Song ; Xie, Jun ; Yan, Zhantao ; Zhang, Xian ; Zong, Yun ; Han-Zhang, Han ; Li, Qing ; Li, Chong</creator><creatorcontrib>Li, Yan ; Tan, Yan ; Hu, Song ; Xie, Jun ; Yan, Zhantao ; Zhang, Xian ; Zong, Yun ; Han-Zhang, Han ; Li, Qing ; Li, Chong</creatorcontrib><description>Lung adenocarcinoma (LADC) is classified into five main histological subtypes with distinct clinicopathologic characteristics: lepidic-predominant adenocarcinoma (LPA), acinar-predominant adenocarcinoma (APA), papillary-predominant adenocarcinoma (PPA), micropapillary-predominant adenocarcinoma (MPA) and solid-predominant adenocarcinoma (SPA). However, the mutational profiles of predominant histological subtypes have not been well defined. In this study, we aimed to reveal the genomic landscape of 5 main histological subtypes. We performed next-generation sequencing (NGS) in a cohort of 86 stage I invasive adenocarcinoma (IAC) patients, using a customized panel including 168 cancer-associated genes. Our analysis identified a total of 302 genomic alterations. Five subtypes showed different mutation profiles with LPA, APA, PPA, MPA and SPA had an average mutation rate of 1.95 (range: 0-5), 2.56 (range: 1-6), 3.5 (range: 1-7), 3.75 (range: 1-8) and 6.05 (range: 2-12), respectively (p=4.17e-06). Driver mutations occurred in 96.55% (83/86) of all patients. EGFR (73.3%), KRAS (9.3%), ALK (4.7%) and MET (4.7%) are the most commonly mutated lung cancer driver genes, TP53 is the top mutated tumor suppressor gene. SPA patients harbored more driver mutations and higher frequency of TP53 than LPA patients. Interestingly, mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p=0.001). No patients from other four cohorts harbored mutations. We revealed distinctive mutation landscape of the 5 major histological subtypes of LADC, evident by distinctive average mutation rate with SPA and LPA having the highest and lowest average mutation rate, respectively. SPA patients showed higher mutation rate of LRP1B and higher rates for PD-L1 positivity, indicating that SPA patients may have better response to immunotherapy.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.51405</identifier><identifier>PMID: 33976731</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Genomes ; Lung cancer ; Lymphatic system ; Medical prognosis ; Metastasis ; Mutation ; Patients ; Research Paper ; Survival analysis</subject><ispartof>Journal of Cancer, 2021-01, Vol.12 (11), p.3222-3229</ispartof><rights>The author(s).</rights><rights>2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-693bceb23a09362bd350ce9d3a15dfa19966d5db38201a4680044e3afa9ce793</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2598309353/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2598309353?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33976731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Tan, Yan</creatorcontrib><creatorcontrib>Hu, Song</creatorcontrib><creatorcontrib>Xie, Jun</creatorcontrib><creatorcontrib>Yan, Zhantao</creatorcontrib><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Zong, Yun</creatorcontrib><creatorcontrib>Han-Zhang, Han</creatorcontrib><creatorcontrib>Li, Qing</creatorcontrib><creatorcontrib>Li, Chong</creatorcontrib><title>Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Lung adenocarcinoma (LADC) is classified into five main histological subtypes with distinct clinicopathologic characteristics: lepidic-predominant adenocarcinoma (LPA), acinar-predominant adenocarcinoma (APA), papillary-predominant adenocarcinoma (PPA), micropapillary-predominant adenocarcinoma (MPA) and solid-predominant adenocarcinoma (SPA). However, the mutational profiles of predominant histological subtypes have not been well defined. In this study, we aimed to reveal the genomic landscape of 5 main histological subtypes. We performed next-generation sequencing (NGS) in a cohort of 86 stage I invasive adenocarcinoma (IAC) patients, using a customized panel including 168 cancer-associated genes. Our analysis identified a total of 302 genomic alterations. Five subtypes showed different mutation profiles with LPA, APA, PPA, MPA and SPA had an average mutation rate of 1.95 (range: 0-5), 2.56 (range: 1-6), 3.5 (range: 1-7), 3.75 (range: 1-8) and 6.05 (range: 2-12), respectively (p=4.17e-06). Driver mutations occurred in 96.55% (83/86) of all patients. EGFR (73.3%), KRAS (9.3%), ALK (4.7%) and MET (4.7%) are the most commonly mutated lung cancer driver genes, TP53 is the top mutated tumor suppressor gene. SPA patients harbored more driver mutations and higher frequency of TP53 than LPA patients. Interestingly, mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p=0.001). No patients from other four cohorts harbored mutations. We revealed distinctive mutation landscape of the 5 major histological subtypes of LADC, evident by distinctive average mutation rate with SPA and LPA having the highest and lowest average mutation rate, respectively. SPA patients showed higher mutation rate of LRP1B and higher rates for PD-L1 positivity, indicating that SPA patients may have better response to immunotherapy.</description><subject>Genomes</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Patients</subject><subject>Research Paper</subject><subject>Survival analysis</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkd9rFDEQx4MottQ--A9IwBd9uJrs7K-8CKWoPThQ7L2H2WR2zbGbnMnuwf335tpaqvOSgXz4MDNfxt5KcdXISnzaGbyqZCmqF-xcttCsVF2XL5_1Z-wypZ3IBapoSnjNzgBUUzcgz1ncYhxoJsvv6PdC3jg_8GuP4zG5xEPPf0SyYXIe_cxvXZrDGAZncOR3Szcf95S48_wnJTL3khkH4mu-9gdM7kB8s5x8lnwwGLM8TPiGvepxTHT5-F6w7dcv25vb1eb7t_XN9WZlSgHzqlbQGeoKQKGgLjoLlTCkLKCsbI9S5d1sZTtoCyGxrFshypIAe1SGGgUX7PODdr90E1lDfo446n10E8ajDuj0vz_e_dJDOOhWCtHKKgs-PApiyKdJs55cMjSO6CksSRdVUecAJJQZff8fugtLzFc8UaqFvEEFmfr4QJkYUorUPw0jhT5lqXOW-j7LzL57Pv0T-Tc5-AOTTJtV</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Li, Yan</creator><creator>Tan, Yan</creator><creator>Hu, Song</creator><creator>Xie, Jun</creator><creator>Yan, Zhantao</creator><creator>Zhang, Xian</creator><creator>Zong, Yun</creator><creator>Han-Zhang, Han</creator><creator>Li, Qing</creator><creator>Li, Chong</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma</title><author>Li, Yan ; Tan, Yan ; Hu, Song ; Xie, Jun ; Yan, Zhantao ; Zhang, Xian ; Zong, Yun ; Han-Zhang, Han ; Li, Qing ; Li, Chong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-693bceb23a09362bd350ce9d3a15dfa19966d5db38201a4680044e3afa9ce793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Genomes</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Patients</topic><topic>Research Paper</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Tan, Yan</creatorcontrib><creatorcontrib>Hu, Song</creatorcontrib><creatorcontrib>Xie, Jun</creatorcontrib><creatorcontrib>Yan, Zhantao</creatorcontrib><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Zong, Yun</creatorcontrib><creatorcontrib>Han-Zhang, Han</creatorcontrib><creatorcontrib>Li, Qing</creatorcontrib><creatorcontrib>Li, Chong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yan</au><au>Tan, Yan</au><au>Hu, Song</au><au>Xie, Jun</au><au>Yan, Zhantao</au><au>Zhang, Xian</au><au>Zong, Yun</au><au>Han-Zhang, Han</au><au>Li, Qing</au><au>Li, Chong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>12</volume><issue>11</issue><spage>3222</spage><epage>3229</epage><pages>3222-3229</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Lung adenocarcinoma (LADC) is classified into five main histological subtypes with distinct clinicopathologic characteristics: lepidic-predominant adenocarcinoma (LPA), acinar-predominant adenocarcinoma (APA), papillary-predominant adenocarcinoma (PPA), micropapillary-predominant adenocarcinoma (MPA) and solid-predominant adenocarcinoma (SPA). However, the mutational profiles of predominant histological subtypes have not been well defined. In this study, we aimed to reveal the genomic landscape of 5 main histological subtypes. We performed next-generation sequencing (NGS) in a cohort of 86 stage I invasive adenocarcinoma (IAC) patients, using a customized panel including 168 cancer-associated genes. Our analysis identified a total of 302 genomic alterations. Five subtypes showed different mutation profiles with LPA, APA, PPA, MPA and SPA had an average mutation rate of 1.95 (range: 0-5), 2.56 (range: 1-6), 3.5 (range: 1-7), 3.75 (range: 1-8) and 6.05 (range: 2-12), respectively (p=4.17e-06). Driver mutations occurred in 96.55% (83/86) of all patients. EGFR (73.3%), KRAS (9.3%), ALK (4.7%) and MET (4.7%) are the most commonly mutated lung cancer driver genes, TP53 is the top mutated tumor suppressor gene. SPA patients harbored more driver mutations and higher frequency of TP53 than LPA patients. Interestingly, mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p=0.001). No patients from other four cohorts harbored mutations. We revealed distinctive mutation landscape of the 5 major histological subtypes of LADC, evident by distinctive average mutation rate with SPA and LPA having the highest and lowest average mutation rate, respectively. SPA patients showed higher mutation rate of LRP1B and higher rates for PD-L1 positivity, indicating that SPA patients may have better response to immunotherapy.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>33976731</pmid><doi>10.7150/jca.51405</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1837-9664
ispartof Journal of Cancer, 2021-01, Vol.12 (11), p.3222-3229
issn 1837-9664
1837-9664
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8100815
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central (PMC)
subjects Genomes
Lung cancer
Lymphatic system
Medical prognosis
Metastasis
Mutation
Patients
Research Paper
Survival analysis
title Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Sequencing%20Analysis%20of%20Predominant%20Histological%20Subtypes%20in%20Resected%20Stage%20I%20Invasive%20Lung%20Adenocarcinoma&rft.jtitle=Journal%20of%20Cancer&rft.au=Li,%20Yan&rft.date=2021-01-01&rft.volume=12&rft.issue=11&rft.spage=3222&rft.epage=3229&rft.pages=3222-3229&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.51405&rft_dat=%3Cproquest_pubme%3E2598309353%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-693bceb23a09362bd350ce9d3a15dfa19966d5db38201a4680044e3afa9ce793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2598309353&rft_id=info:pmid/33976731&rfr_iscdi=true